Michael H. Tardugno, Executive Chairman of the Board of Imunon, Inc., filed a Form 4 on October 27, 2026, disclosing an acquisition of 6,821 shares of common stock on October 23, 2026, granted in lieu of cash for base salary.

Key Highlights

  • Reporting person: Michael H. Tardugno, serving as Executive Chairman of the Board and a Director of Imunon, Inc. (NASDAQ:IMNN).
  • Transaction: 6,821 shares of common stock acquired (transaction code A) on October 23, 2026, at a price of $1.235 per share.
  • Purpose of grant: The filing states the stock was "granted in lieu of cash for base salary."
  • Direct holdings after transaction: 118,542 shares of common stock held directly following the reported transaction.
  • Indirect holdings: 4,622 shares of common stock held indirectly, described as held by IRA.
  • Filed by: Jeffrey W. Church, Attorney in Fact for Michael H. Tardugno, on October 27, 2026.

Imunon Executive Chairman Receives Salary-Based Stock Grant in October 2026

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Michael H. Tardugno, Executive Chairman of the Board at Imunon, Inc. (NASDAQ:IMNN), acquired 6,821 shares of the company's common stock on October 23, 2026. The filing identifies the transaction code as "A" (acquired) and states the per-share price as $1.235. The filing's footnote explains that the stock was "granted in lieu of cash for base salary," indicating a compensation arrangement rather than an open-market purchase.

Following this transaction, the filing reports that Tardugno directly holds 118,542 shares of Imunon common stock. In addition, the filing discloses 4,622 shares held indirectly through an IRA, with no changes reported to that indirect position in this filing. No derivative securities transactions were reported in Table II of the form.

The Form 4 was signed by Jeffrey W. Church as Attorney in Fact for Michael H. Tardugno and submitted on October 27, 2026. The filing does not indicate that the transaction was made pursuant to a Rule 10b5-1(c) trading plan, as the corresponding checkbox was not selected.

What Was Disclosed

Imunon's Executive Chairman Michael H. Tardugno disclosed an acquisition of 6,821 common shares on October 23, 2026, at $1.235 per share as compensation in lieu of cash salary, bringing his direct beneficial ownership to 118,542 shares, with 4,622 additional shares held indirectly via an IRA.